Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Lukasz, Skalniak"'
Autor:
Ismael Rodriguez, Justyna Kocik-Krol, Lukasz Skalniak, Bogdan Musielak, Aneta Wisniewska, Agnieszka Ciesiołkiewicz, Łukasz Berlicki, Jacek Plewka, Przemyslaw Grudnik, Malgorzata Stec, Maciej Siedlar, Tad A. Holak, Katarzyna Magiera-Mularz
Publikováno v:
Molecular Cancer, Vol 22, Iss 1, Pp 1-8 (2023)
Abstract Recent advances in immuno-oncology have opened up new and impressive treatment options for cancer. Notwithstanding, overcoming the limitations of the current FDA-approved therapies with monoclonal antibodies (mAbs) that block the PD-1/PD-L1
Externí odkaz:
https://doaj.org/article/4d89b666a61e477c85c3abb086044bda
Autor:
Katarzyna Magiera-Mularz, Justyna Kocik, Bogdan Musielak, Jacek Plewka, Dominik Sala, Monika Machula, Przemyslaw Grudnik, Malgorzata Hajduk, Marcin Czepiel, Maciej Siedlar, Tad A. Holak, Lukasz Skalniak
Publikováno v:
iScience, Vol 24, Iss 1, Pp 101960- (2021)
Summary: In the development of PD-L1-blocking therapeutics, it is essential to transfer initial in vitro findings into proper in vivo animal models. Classical immunocompetent mice are attractive due to high accessibility and low experimental costs. H
Externí odkaz:
https://doaj.org/article/60bd188bec4540759a79eec5931735b6
Autor:
Shabnam Shaabani, Louis Gadina, Ewa Surmiak, Zefeng Wang, Bidong Zhang, Roberto Butera, Tryfon Zarganes-Tzitzikas, Ismael Rodriguez, Justyna Kocik-Krol, Katarzyna Magiera-Mularz, Lukasz Skalniak, Alexander Dömling, Tad A. Holak
Publikováno v:
Molecules, Vol 27, Iss 11, p 3454 (2022)
New biphenyl-based chimeric compounds containing pomalidomide were developed and evaluated for their activity to inhibit and degrade the programmed cell death-1/programmed cell death- ligand 1 (PD-1/PD-L1) complex. Most of the compounds displayed exc
Externí odkaz:
https://doaj.org/article/67a2552841844f3d9aa8c069ce56167b
Autor:
Ewa Surmiak, Julia Ząber, Jacek Plewka, Grzegorz Wojtanowicz, Justyna Kocik-Krol, Oskar Kruc, Damian Muszak, Ismael Rodríguez, Bogdan Musielak, Lukasz Skalniak, Katarzyna Magiera-Mularz, Tad A. Holak, Justyna Kalinowska-Tłuścik
Although heavily studied, the subject of anti-PD-L1 small molecular inhibitors is still elusive. Here, we present a systematic overview of principles behind the successful anti-PD-L1 small molecule inhibitor design on the example of the m-terphenyl s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f42c65749e6269f9d19dc3dd7e995559
https://doi.org/10.21203/rs.3.rs-2907891/v1
https://doi.org/10.21203/rs.3.rs-2907891/v1
Autor:
Bogdan Musielak, Justyna Kocik, Lukasz Skalniak, Katarzyna Magiera-Mularz, Dominik Sala, Miroslawa Czub, Malgorzata Stec, Maciej Siedlar, Tad A. Holak, Jacek Plewka
Publikováno v:
Molecules, Vol 24, Iss 15, p 2804 (2019)
CA-170 is currently the only small-molecule modulator in clinical trials targeting PD-L1 and VISTA proteins − important negative checkpoint regulators of immune activation. The reported therapeutic results to some extent mimic those of FDA-approved
Externí odkaz:
https://doaj.org/article/7d516a7031dd4e9d8d1e8fdf4cde5b5c
Autor:
Maciej Siedlar, Lukasz Skalniak, Ismael Rodríguez, Dominik Sala, Tad A. Holak, Magdalena Konieczny, Jacek Plewka, Justyna Kocik, Małgorzata Stec, Katarzyna Magiera-Mularz, Miroslawa Czub, Maja Myrcha, Bogdan Musielak
Publikováno v:
Journal of Medicinal Chemistry
Immune checkpoint blockade is one of the most promising strategies of cancer immunotherapy. However, unlike classical targeted therapies, it is currently solely based on expensive monoclonal antibodies, which often inflict immune-related adverse even
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::032cc6b5402219d3d1dd54b8c4307ac8
http://europepmc.org/articles/PMC7584369
http://europepmc.org/articles/PMC7584369
Autor:
Lukasz Skalniak, Radoslaw Kitel, Jacek Plewka, Tad A. Holak, Bogdan Musielak, Damian Muszak, Ewa Surmiak, Justyna Kocik-Krol, Katarzyna Magiera-Mularz
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 11797, p 11797 (2021)
International Journal of Molecular Sciences
International Journal of Molecular Sciences
Targeting the programmed cell death protein 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) interaction has become an established strategy for cancer immunotherapy. Although hundreds of small-molecule, peptide, and peptidomimetic inhibitors have been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f846fc8bfbfa8eca4fdf24197328b1f
https://pubmed.ncbi.nlm.nih.gov/34769226
https://pubmed.ncbi.nlm.nih.gov/34769226
Autor:
Lukasz Skalniak, Dominik Sala, Alexander Dömling, Justyna Kocik-Krol, Tad A. Holak, Katarzyna Magiera-Mularz, Radoslaw Kitel, Kazimierz Weglarczyk, Jacek Plewka, Damian Muszak, Ewa Surmiak, Małgorzata Stec, Maciej Siedlar, Bogdan Musielak
Publikováno v:
Journal of Medicinal Chemistry, 64(15), 11614-11636. AMER CHEMICAL SOC
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry
We describe a new class of potent PD-L1/PD-1 inhibitors based on a terphenyl scaffold that is derived from the rigidified biphenyl-inspired structure. Using in silico docking, we designed and then experimentally demonstrated the effectiveness of the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea0e35ef9495ca462e48490a926d997d
https://ruj.uj.edu.pl/xmlui/handle/item/277678
https://ruj.uj.edu.pl/xmlui/handle/item/277678
Autor:
Tad A. Holak, Dominik Sala, Katarzyna Magiera-Mularz, Benedykt Wladyka, Grzegorz Dubin, Jacek Plewka, Justyna Kocik, Kazimierz Weglarczyk, Małgorzata Stec, Lukasz Skalniak, Bogdan Musielak, Przemyslaw Grudnik, Katarzyna Kuska, Maciej Siedlar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c76cc20b42efff5f1685b0af242ab16
https://ruj.uj.edu.pl/xmlui/handle/item/267441
https://ruj.uj.edu.pl/xmlui/handle/item/267441